Although they were quite volatile at times, in the end Australian pot stocks provided investors with some of the best returns on the market last year.
While there's no guarantee that this will be the case again in 2018, below are three pot stocks which I feel are positioned well to push higher this year:
Auscann Group Holdings Ltd (ASX: AC8)
Although regulations have been loosening in Australia, there's still a lot of work to do before medicinal cannabis is readily available for sufferers of chronic pain and other ailments. But AusCann is pushing hard for change and if it comes will be well-positioned to profit. Approximately 20% of Australians are believed to suffer from chronic pain, making it an extremely lucrative market for the medicinal cannabis producers.
Botanix Pharmaceuticals Ltd (ASX: BOT)
Botanix is currently conducting a trial of its BTX 1503 candidate which uses synthetic cannabidiol to treat moderate to severe acne. I believe a new treatment for acne is long overdue and that BTX 1503 could win a significant share of the US$4.5 billion acne prescription market if its trials are a success. After all, the current go-to treatment, Accutane, is both expensive and has horrific side effects.
Creso Pharma Ltd (ASX: CPH)
I think that Creso Pharma will be one to watch in 2018 due to the expansion of its business towards the end of last year. This included a move into edibles, China, and the recreational market in Canada. All in all, I think this cashed-up cannabis company could be on the verge of generating material revenues.
